Advertisement

Clinical decision making in breast cancer: TAM and aromatase inhibitors for older patients - a jungle?

Published:August 15, 2007DOI:https://doi.org/10.1016/j.ejca.2007.07.007

      Abstract

      Aromatase inhibitors and inactivactors (AIs) have been/are being widely investigated as an alternative to tamoxifen in the treatment of postmenopausal breast cancer patients. In this paper we have reviewed data from phase III studies to define the role of AIs versus tamoxifen as first-line therapy in patients with metastatic breast cancer, as primary therapy for not operable or early breast cancers not suitable for conservative surgery and as adjuvant treatment for women with early breast cancer. An effort has been performed to evaluate whether specific recommendations were needed for older postmenopausal patients.
      AIs play a key role in the treatment of advanced breast cancer and represent the agent of choice in patients who are candidates to neoadjuvant hormone-therapy. Longer follow-up of already published trials and additional data coming from ongoing studies will better define when and how to use AIs in the adjuvant setting.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Nabholtz J.M.
        • Buzdar A.
        • Pollak M.
        • et al.
        Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group.
        J Clin Oncol. 2000; 18: 3758-3767
        • Bonneterre J.
        • Thurlimann B.
        • Robertson J.F.R.
        • et al.
        Anastrozole versus tamoxifen as first-line therapy for advanced breast carcinoma in postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficay and Tolerability study.
        J Clin Oncol. 2000; 18: 3748-3757
        • Bonneterre J.
        • Buzdar A.
        • Nabholtz J.M.
        • et al.
        Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma.
        Cancer. 2001; 92: 2247-2258
        • Paridaens R.
        • Therasse P.
        • Dirix L.
        • et al.
        First line hormonal treatment (HT) for metastatic breast cancer (BMC) with exemestane (E) or tamoxifen (T) in postmenopausal patients (pts) : a randomized phase III trial of the EORTC Breast Group.
        J Clin Oncol. 2004; 22 (abstract 515)
        • Mouridsen H.
        • Gershanovich M.
        • Sun Y.
        • et al.
        Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group.
        J Clin Oncol. 2003; 21: 2101-2109
        • Nabholtz J.M.
        • Bonneterre J.
        • Buzdar A.
        • Robertson J.F.
        • Thurlimann B.
        Anastrozole (Arimidex) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: survival analysis and updated safety results.
        Eur J Cancer. 2003; 39: 1684-1689
        • Mauri D.
        • Pavlidis N.
        • Polyzos N.P.
        • Ioannidis J.P.A.
        Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysis.
        J Natl Cancer Inst. 2006; 98: 1285-1291
        • Karnon J.
        Aromatase inhibitors in breast cancer: a review of cost considerations and cost effectiveness.
        Pharmacoeconomics. 2006; 24: 215-232
        • Venturino A.
        • Comandini D.
        • Granetto C.
        • et al.
        Formestane is feasible and effective in elderly breast cancer patients with comorbidity and disability.
        Breast Cancer Res Treat. 2000; 62: 217-222
        • Smith I.
        • Dowsett M.
        • Ebbs S.R.
        • et al.
        Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial.
        on behalf of IMPACT trialists. J Clin Oncol. 2005; 23: 5108-5116
        • Cataliotti L.
        • Buzdar A.
        • Noguchi S.
        • et al.
        Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer: the Pre-Operative Arimidex” Compared to Tamoxifen (PROACT) trial.
        Cancer. 2006; 106: 2095-2103
        • Semiglazov V.F.
        • Kletsel A.
        • Semiglazov V.V.
        • et al.
        Exemestane (E) vs Tamoxifen (T) as neoadjuvant endocrine therapy for postmenopausal women with ER+ breast cancer (T2N1-2, T3N0-1,T4N0M0).
        J Clin Oncol. 2005; 23: 530
        • Eiermann W.
        • Paepke S.
        • Appfelstaedt J.
        • et al.
        Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study.
        Ann Oncol. 2001; 12: 1527-1532
        • Ellis M.J.
        • Coop A.
        • Singh B.
        • et al.
        Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial.
        J Clin Oncol. 2001; 19: 3808-3816
        • Dowset M.
        • Allred D.C.
        • et al.
        Relationship between quantitative ER and PgR expression and HER2 status with recurrence in the ATAC trial.
        Breast Cancer Res Treat. 2006; 100 (abstract 48): S21
        • The ATAC Trialists’ Group
        Anastrozol alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial.
        Lancet. 2002; 359: 2131-2139
        • ATAC Trialists’ Group
        Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer.
        Lancet. 2005; 365: 60-62
        • Coates A.S.
        • Keshaviah A.
        • Thurlimann B.
        • et al.
        Five years of letrozole compared with tamoxifen as initial therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98.
        J Clin Oncol. 2007; 25: 486-492
        • Coombes R.C.
        • Kilburn L.S.
        • Snowdon C.F.
        • et al.
        Survival and safety of exemestane versus tamoxifen after 2-3 years’ tamoxifen treatment (Intergroup Exemestane Study): a randomized controlled trial.
        Lancet. 2007; 369: 559-570
        • Jonat W.
        • Gnant M.
        • Boccardo F.
        • et al.
        Effectiveness of switching from adjuavant tamoxifen to anastrozole in postmenopausal women with hormone-sensitive early stage breast cancer: a meta-analysis.
        Lancet. 2006; 7: 991-996
        • Goss P.E.
        • Ingle J.N.
        • Martino S.
        • et al.
        A randomised trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.
        N Engl J Med. 2003; 349: 1793-1802
        • Goss P.E.
        • Ingle J.N.
        • Martino S.
        • et al.
        Randomised trial of letrozole following tamoxifen as adjuvant therapy in receptor-positive breast cancer: update findings from NCIC CTG MA.17.
        J Natl Cancer Inst. 2005; 97: 1262-1271
        • Ingle J.
        • Du T.
        • Shepherd L.
        • Palmer M.
        • Pater J.
        • Goss P.
        NCI CTG MA.17: Intent to treat analysis (ITT) of randomized patients after a median follow-up of 54 months.
        J Clin Oncol. 2006; 24 (abstract 549)
        • Jakesz R.
        • Samonigg H.
        • Greil R.
        • et al.
        Extended adjuvant treatment with anastrozole: results from the Austrian Breast and Colorectal Cancer Study Group Trial 6a (ABCSG-6a).
        J Clin Oncol. 2005; 23 (abstract 527)
        • Winer E.P.
        • Hudis C.
        • Burstein H.J.
        • et al.
        American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004.
        J Clin Oncol. 2005; 23: 619-629
        • Jakesz R.
        • Jonat W.
        • Gnant M.
        • et al.
        Switching of postmenopausal women with endocrine-responsive early breast cancer to anstrozole after 2 years’ adjuvant tamoxifen : combined results of ABCSG trial 8 and ARNO 95 trial.
        Lancet. 2005; 366: 455-462
        • Early Breast Cancer Trialists’ Collaborative Group
        Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.
        Lancet. 2005; 365: 1687-1717
        • Muss H.B.
        • Tu D.
        • Ingle J.N.
        • et al.
        The benefits of letrozole in postmenopausal women with early stage breast cancer who have had five years of tamoxifen are independent of age.
        Breast Cancer Res Treat. 2006; 100 (abstract 102): S23
        • Coleman R.E.
        • Banks L.M.
        • Girgis S.I.
        • et al.
        Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomized controlled study.
        Lancet. 2007; 8: 119-127
        • Gass M.
        • Dawson-Hughes B.
        Preventing osteoporosis-related fracture: an overview.
        Am J Med. 2006; 119: S3-S11
        • The Arimidex Tamoxifen, Alone or in Combination (ATAC) Trialists’ Group
        Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial.
        Lancet Oncol. 2006; 7: 633-643
        • Boccardo F.
        • Rubagotti A.
        • Puntoni M.
        • et al.
        Switching to anastrozole versus continued tamoxifen treatment of early breast cancer/ preliminary results of the Italian Tamoxifen Anastrozole Trial.
        J Clin Oncol. 2005; 23: 5138-5147
        • Saphner T.
        • Tormey D.C.
        • Gray R.
        Annual hazard rates of recurrence for breast cancer after primary therapy.
        J Clin Oncol. 1996; 14: 2738-2746
        • Kennecke H.F.
        • Olivotto I.A.
        • Speers C.
        • et al.
        Late risk of relapse and mortality among postmenopausal women with estrogen responsive early breast cancer after 5 years of tamoxifen.
        Ann Oncol. 2007; 18: 45-51
        • Brufsky A.
        • Harker W.G.
        • Beck J.T.
        • et al.
        Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer.
        J Clin Oncol. 2007; 25: 829-836
        • Lewis J.H.
        • Kilgore M.L.
        • Goldman D.P.
        • et al.
        Participation of patients 65 years of age or older in cancer clinical trials.
        J Clin Oncol. 2003; 21: 1383-1389